Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

RenovoRx, Inc. - Common Stock (NQ: RNXT )

0.9858 -0.0342 (-3.35%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 16,533
Open 1.040
Bid (Size) 0.9600 (1)
Ask (Size) 1.020 (2)
Prev. Close 1.020
Today's Range 0.9600 - 1.040
52wk Range 0.7736 - 1.820
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
RenovoRx Advances Commercialization of RenovoCath® with Several New Purchase Orders, Including Customer Reorders
From RenovoRx, Inc.
Via Business Wire
RenovoRx Highlights Promising Pre-Clinical Data Abstract: TAMP™ Therapy Platform Offers Potential to Improve Localized and Targeted Drug Delivery
From RenovoRx, Inc
Via Business Wire

Performance

YTD
-27.51%
-27.51%
1 Month
-14.28%
-14.28%
3 Month
-25.32%
-25.32%
6 Month
-7.87%
-7.87%
1 Year
-40.61%
-40.61%

More News

Read More
BioMedNewsBreaks – RenovoRx Inc. (NASDAQ: RNXT) Announces $12.1M Underwritten Public Offering
Via Investor Brand Network
Exposures Product Safety
RNXT Stock Earnings: RenovoRx Meets EPS for Q2 2024
Via InvestorPlace
RNXT Stock Earnings: RenovoRx Beats EPS for Q1 2024
Via InvestorPlace
RenovoRx Announces Closing of $12.1 Million Underwritten Public Offering of Common Stock
From RenovoRx, Inc.
Via Business Wire
What's going on in today's pre-market session
Via Chartmill
RenovoRx Announces Pricing of $12.1 Million Underwritten Public Offering of Common Stock
From RenovoRx, Inc.
Via Business Wire
These stocks are moving in today's after hours session
Via Chartmill
RenovoRx Announces Proposed Public Offering
From RenovoRx, Inc.
Via Business Wire
RenovoRx Highlights Promising Pharmacokinetic Data Abstract Presented at ASCO GI 2025
From RenovoRx, Inc.
Via Business Wire
RenovoRx Announces Acceptance of Abstract for Presentation at ASCO Gastrointestinal Cancers Symposium 2025
From RenovoRx, Inc.
Via Business Wire
RenovoRx Continues to Grow Intellectual Property Portfolio for its Novel Drug-Delivery Therapy Platform
From RenovoRx, Inc.
Via Business Wire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Exact Sciences To Rally Around 33%? Here Are 10 Top Analyst Forecasts For Thursday
Via Benzinga
Why AMMO Shares Are Trading Lower By Over 19%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
RenovoRx CEO Issues Update Letter to Shareholders
From RenovoRx, Inc.
Via Business Wire
Publication of Results of Pre-Clinical Studies Support Efficacy and Drug Delivery Mechanism Potential of RenovoRx’s TAMP™ Therapy Platform to Improve Targeted Cancer Drug Treatment Delivery
From RenovoRx, Inc.
Via Business Wire
RenovoRx to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase on May 21, 2024
From RenovoRx, Inc.
Via Business Wire
RenovoRx CEO Shaun R. Bagai to Present at the Aegis Capital Virtual Conference on May 9, 2024
From RenovoRx, Inc.
Via Business Wire
RenovoRx Regains Compliance with Nasdaq Stockholders’ Equity Requirement
From RenovoRx , Inc.
Via Business Wire
RenovoRx Highlights Recent Presentation of Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting
From RenovoRx, Inc.
Via Business Wire
RenovoRx Closes $11.1 Million Private Placement, Providing Cash Runway into 2026
From RenovoRx, Inc.
Via Business Wire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Via InvestorPlace
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.